Mosunetuzumab with polatuzumab vedotin effective in range of age groups with DLBCL

NEW ORLEANS — Mosunetuzumab with polatuzumab vedotin showed efficacy in patients with diffuse large B-cell lymphoma who are younger and older than 65 years, according to research presented at the ASH Annual Meeting and Exhibition.The overall response rate was 54% in younger patients and 72% in older patients, Adam J. Olszewski, MD, presenting author, said.

Related Keywords

Rhode Island ,United States ,Mindy Valcarcel ,Bycory Perla ,Adamj Olszewski ,Genentech ,Brown Physicians Inc ,Brown University Warren Alpert Medical School ,Adaptive Biotechnologies Genentech ,Blue Cross ,Blue Shield ,Brown Physicians ,Brown University ,Warren Alpert Medical School ,